Micromolar concentrations of citalopram or escitalopram inhibit glycoprotein VI-mediated and integrin αIIbβ3-mediated signaling in human platelets

Toxicology and Applied Pharmacology

Volumn 364, Issue , 2019, Pages 106-113

  Tseng, Yu Lun ^a,g   Braun, Attila ^b   Chang, Jane Pei Chen ^c   Chiang, Meng Ling ^d   Tseng, Chi Yu ^e,g   Chen, Wenchun ^f  

^a Taipei Tzuchi Hospital   (Taiwan)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e Buddhist General Tzu Chi Hospital   (Taiwan)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Citalopram; Escitalopram; Platelet function; Selective serotonin reuptake inhibitor; Syk

Indexed keywords

CITALOPRAM; CONVULXIN; ESCITALOPRAM; FC RECEPTOR; FIBRINOGEN; GLYCOPROTEIN VI; INTEGRIN; P21 ACTIVATED KINASE; PROTEIN KINASE B; PROTEIN KINASE SYK; SEROTONIN; SEROTONIN TRANSPORTER; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; LAT PROTEIN, HUMAN; LECTIN; MEMBRANE PROTEIN; PLATELET MEMBRANE GLYCOPROTEIN VI; SEROTONIN UPTAKE INHIBITOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SNAKE VENOM; SYK PROTEIN, HUMAN;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LAMELLIPODIUM; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEROTONIN RELEASE; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION; PSEUDOPODIUM; THROMBOCYTE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOOD PLATELETS; CITALOPRAM; CROTALID VENOMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; HUMANS; LECTINS, C-TYPE; MEMBRANE PROTEINS; P21-ACTIVATED KINASES; PHOSPHORYLATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PSEUDOPODIA; RECEPTORS, IGG; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION; SYK KINASE;

EID: 85059188061     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2018.12.016     Document Type: Article

References (43)

1. Aslan, J.E., Itakura, A., Haley, K.M., Tormoen, G.W., Loren, C.P., Baker, S.M., Pang, J., Chernoff, J., McCarty, O.J., p21 activated kinase signaling coordinates glycoprotein receptor VI-mediated platelet aggregation, lamellipodia formation, and aggregate stability under shear. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 1544–1551.
2. Bampalis, V.G., Khandoga, A.L., Siess, W., Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood. Thromb. Haemost. 104 (2010), 1272–1274.
3. Bampalis, V.G., Dwivedi, S., Shai, E., Brandl, R., Varon, D., Siess, W., Effect of 5-HT2A receptor antagonists on human platelet activation in blood exposed to physiologic stimuli and atherosclerotic plaque. J. Thromb. Haemost. 9 (2011), 2112–2115.
4. Bismuth-Evenzal, Y., Gonopolsky, Y., Gurwitz, D., Iancu, I., Weizman, A., Rehavi, M., Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J. Affect. Disord. 136 (2012), 99–103.
5. Boylan, B., Gao, C., Rathore, V., Gill, J.C., Newman, D.K., Newman, P.J., Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets. Blood 112 (2008), 2780–2786.
6. Carneiro, A.M.D., Cook, E.H., Murphy, D.L., Blakely, R.D., Interactions between integrin αIIbβ3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J. Clin. Invest. 118 (2008), 1544–1552.
7. Chittaranjan, A., Chethan, K.B., Sandarsh, S., Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure. Int. Clin. Psychopharmacol. 28 (2013), 145–155.
8. Durrant, T.N., van den Bosch, M.T., Hers, I., Integrin αIIbβ3 outside-in signaling. Blood 130 (2017), 1607–1618.
9. Dutting, S., Bender, M., Nieswandt, B., Platelet GPVI: a target for antithrombotic therapy?!. Trends Pharmacol. Sci. 33 (2012), 583–590.
10. van Eeuwijk, J.M., Stegner, D., Lamb, D.J., Kraft, P., Beck, S., Thielmann, I., Kiefer, F., Walzog, B., Stoll, G., Nieswandt, B., The novel oral Syk inhibitor, Bl1002494, protects mice from arterial thrombosis and thromboinflammatory brain infraction. Arterioscler. Thromb. Vasc. Biol. 36 (2016), 1247–1253.
11. Flöck, A., Zobel, A., Bauriedel, G., Tuleta, I., Hammerstingl, C., Hofels, S., Schuhmacher, A., Maier, W., Nickenig, G., Skowasch, D., Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline. Thromb. Res. 126 (2010), e83–e87.
12. Hyttel, J., Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 6 (1982), 277–295.
13. Kahl, K.G., Westhoff-Bleck, M., Krüger, T.H., Effects of psychopharmacological treatment with antidepressants on the vascular system. Vasc. Pharmacol. 96-98 (2017), 11–18.
14. Labos, C., Dasgupta, K., Nedjar, H., Turecki, G., Rahme, E., Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infraction. CMAJ 183 (2011), 1835–1843.
15. Letourneur, O., Kennedy, I.C., Brini, A.T., Ortaldo, J.R., O'Shea, J.J., Kinet, J.P., Characterization of the family of dimers associated with Fc receptors (Fc epsilon RI and Fc gamma RIII). J. Immunol. 147 (1991), 2652–2656.
16. Lin, O.A., Karim, Z.A., Vemana, H.P., Espinosa, E.V., Khasawneh, F.T., The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. PLoS One, 9, 2014, e87026.
17. Lopez-Vilchez, I., Jerez-Dolz, D., Diaz-Ricart, M., Navarro, V., Zafar, M.U., Zamorano-Leon, J., Lopez-Farre, A., Badimon, J.J., Gasto, C., Escolar, G., Escitalopram impairs thrombin-induced platelet response, cytoskeleton assembly and activation of associated signalling pathways. Thromb. Haemost. 117 (2017), 2312–2321.
18. Maurer-Spurej, E., Dyker, K., Gahl, W.A., Devine, D.V., A novel immunocytochemical assay for the detection of serotonin in platelets. Br. J. Haematol. 116 (2002), 604–611.
19. Maurer-Spurej, E., Pittendreigh, C., Solomons, K., The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb. Haemost. 91 (2004), 119–128.
20. Mercado, C.P., Kilic, F., Molecular mechanism of SERT in platelets: Regulation of plasma serotonin levels. Mol. Interv. 10 (2010), 231–241.
21. Mocsai, A., Ruland, J., Tybulewicz, V.L.J., The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10 (2010), 387–402.
22. Nieswandt, B., Watson, S.P., Platelet-collagen interaction: is GPVI the central receptor?. Blood 102 (2003), 449–461.
23. Nieswandt, B., Bergmeier, W., Eckly, A., Schulte, V., Ohimann, P., Cazenave, J.P., Zirngibi, H., Offermanns, S., Gachet, C., Evidence for cross-talk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation. Blood 97 (2001), 3829–3835.
24. Nurden, A., Nurden, P., Advances in our understanding of the molecular basis of disorders of platelet function. J. Thromb. Haemost. 9 (2011), 76–91 Suppl. 1.
25. Obergfell, A., Eto, K., Mocsai, A., Buensuceso, C., Moores, S.L., Brugge, J.S., Lowell, C.A., Shattil, S.J., Coordinate interactions of Csk, Src, and Syk kinases with αIIbβ3 initiate integrin signaling to the cytoskeleton. J. Cell Biol. 157 (2002), 265–275.
26. 2A receptor. J. Biol. Chem. 291 (2016), 20210–20219.
27. Pavanetto, M., Zarpellon, A., Borgo, C., Donella-Deana, A., Deana, R., Regulation of serotonin transport in human platelets by tyrosine kinase Syk. Cell. Physiol. Biochem. 27 (2011), 139–148.
28. Poole, A., Gibbins, J.M., Turner, M., van Vugt, M.J., van de Winkel, J.G.J., Saito, T., Tybulewicz, V.L.J., Watson, S.P., The Fc receptor γ-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J. 16 (1997), 2333–2341.
29. Quek, L.S., Pasquet, J.M., Hers, I., Cornall, R., Knight, G., Barnes, M., Hibbs, M.L., Dunn, A.R., Lowell, C.A., Watson, S.P., Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway. Blood 96 (2000), 4246–4253.
30. Reddy, K.K., Lefkove, B., Chen, L.B., Govindarajan, B., Carracedo, A., Velasco, G., Carrillo, C.O., Bhandarkar, S.S., Owens, M.J., Mechta-Grigoriou, F., Arbiser, J.L., The antidepressant sertraline downregulates Akt and has activity against melanoma cells. Pigment Cell Melanoma Res. 21 (2008), 451–456.
31. Reid, S., Barbui, C., Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ, 340, 2010, c1468.
32. Roweth, H.G., Yan, R., Bedwani, N.H., Chauhan, A., Fowler, N., Watson, A.H., Malcor, J.D., Sage, S.O., Jarvis, G.E., Citalopram inhibits platelet function independently of SERT-mediated 5-HT transport. Sci. Rep., 8, 2018, 3494.
33. Salsmann, A., Schaffner-Reckinger, E., Kabile, F., Plancon, S., Kieffer, N., A new functional role of fibrinogen RGD motif as the molecular switch that selectively triggers integrin αIIbβ3-dependent RhoA activation during cell spreading. J. Biol. Chem. 280 (2005), 33610–33619.
34. Senis, Y.A., Mazharian, A., Mori, J., Src family kinases: at the forefront of platelet activation. Blood 124 (2014), 2013–2024.
35. Singh, R., Central role of PI3K-SYK interaction in fibrinogen-induced lamellipodia and filopodia formation in platelets. FEBS Open Bio. 6 (2016), 1285–1296.
36. Spalton, J.C., Mori, J., Pollitt, A.Y., Hughes, C.E., Eble, J.A., Watson, S.P., The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. J. Thromb. Haemost. 7 (2009), 1192–1199.
37. Teply, R.M., Packard, K.A., White, N.D., Hilleman, D.E., DiNicolantonio, J.J., Treatment of depression in patients with concomitant cardiac disease. Prog. Cardiovasc. Dis. 58 (2016), 514–528.
38. Tseng, Y.L., Chiang, M.L., Huang, T.F., Su, K.P., Lane, H.Y., Lai, Y.C., A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb. Res. 126 (2010), 517–523.
39. 12 receptor-mediated amplification of platelet aggregation. Thromb. Res. 131 (2013), 325–332.
40. Walther, D.J., Peter, J., Winter, S., Holtje, M., Paulmann, N., Grohmann, M., Vowinckel, J., Alamo-Bethencourt, V., Wilhelm, C.S., Ahnert-Hilger, G., Bader, M., Serotonylation of small GTPase is a signal transduction pathway that triggers platelet α-granule release. Cell 115 (2003), 851–862.
41. White, K.J., Walline, C.C., Barker, E.L., Serotonin Transporters: Implications for antidepressant drug development. AAPSJ 7 (2005), E421–E433.
42. Wolf, K., Braun, A., Haining, E.J., Tseng, Y.L., Kraft, P., Schuhmann, M.K., Gotru, S.K., Chen, W., Hermanns, H.M., Stoll, G., Lesch, K.P., Nieswandt, B., Partially defective store operated calcium and hem(ITAM) signaling in platelets of serotonin transporter deficient mice. PLoS One, 11, 2016, e0147664.
43. Zheng, Y.M., Liu, C., Chen, H., Locke, D., Ryan, J.C., Kahn, M.L., Expression of the platelet receptor GPVI confers signaling via the Fc receptor γ-Chain in response to the snake venom convulxin but not to collagen. J. Biol. Chem. 276 (2001), 12999–13006.